8 terminated, 7 completed, 5 not yet recruiting, 2 active not recruiting. 26 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Terminated 8, Completed 7, Not yet recruiting 5, Active not recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Vaso-Occlusive Crises: new trials by email Literature Review of Vaso-Occlusive Crises trials Research Report on Vaso-Occlusive Crises
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease Iloprost, Placebo - Vaso-Occlusive Crises, Sickle Cell Disease | Phase 3 | Not yet recruiting | University Hospital, Rouen | 144 | 2026-09-01 | 2026-03-27 |
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department Parecoxib, Morphine - Sickle-Cell Disease with Crisis | Phase 3 | Not yet recruiting | Oman Medical Speciality Board | 226 | 2026-05-01 | 2025-03-20 |
| Optimal Timing of Ketamine Initiation for SCD Pain Ketamine hydrochloride injection, Placebo - Sickle Cell Disease, Sickle Cell Crisis | Phase 3 | Not yet recruiting | Boston Children's Hospital | 90 | 2026-02-01 | 2026-03-09 |
| A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis L-citrulline, Placebo - Sickle Cell Disease | Phase 3 | Not yet recruiting | Asklepion Pharmaceuticals, LLC | 120 | 2025-07-25 | 2025-05-29 |
| A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) Crizanlizumab, Placebo - Sickle Cell Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 354 | 2024-10-24 | 2026-10-15 |
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Sufentanil - Vaso-occlusive Crisis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 182 | 2024-05-02 | 2023-12-26 |
| Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) HBOT in Hyperbaric chamber, Hyperbaric chamber for placebo - Sickle Cell Disease, Hyperbaric Oxygen Therapy | Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-09-15 | 2022-11-02 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| Interest of Famotidine in Children With Sickle Cell Disease Famotidine 400 mg/50 mL - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2022-01-12 | 2025-10-08 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults. Sufentanil, EMONO - Sickle Cell Crisis | Phase 3 | Terminated | University Hospital, Bordeaux | 115 | 2021-07-20 | 2026-06-22 |
| A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets - Sickle Cell Disease | Phase 3 | Active not recruiting | Forma Therapeutics, Inc. | 450 | 2021-01-29 | 2026-04-06 |
| Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. Brilinta, Placebo - Sickle Cell Disease | Phase 3 | Withdrawn | AstraZeneca | 2020-06-30 | 2020-07-15 | |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Crizanlizumab (SEG101), Placebo - Sickle Cell Disease (SCD) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 253 | 2019-07-26 | 2026-10-14 |
| Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Ticagrelor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | AstraZeneca | 193 | 2018-09-26 | 2021-04-09 |
| Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Terminated | GlycoMimetics Incorporated | 154 | 2015-12-16 | 2021-02-10 |
Showing 20 of 26. Sign in to see all of them.
Anemia, Sickle Cell (23) · Hematologic Diseases (6) · Sickle Cell Trait (5) · Agnosia (3) · Acute Chest Syndrome (2) · Anemia (1) · Anemia, Hemolytic (1) · Genetic Diseases, Inborn (1) · Hemoglobinopathies (1) · Hemolysis (1) · Pain (1)
Anemia, Hemolytic, Congenital (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Hemic and Lymphatic Diseases (26) · Anemia (25) · Anemia, Hemolytic (25) · Genetic Diseases, Inborn (25) · Hemoglobinopathies (25) · Hematologic Diseases (20) · Pathological Conditions, Signs and Symptoms (5) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Anemia, Sickle Cell (3) · Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Perceptual Disorders (3)
inclacumab (3) · Morphine (2) · Sufentanil (2) · Ticagrelor (2) · crizanlizumab (2) · rivipansel (2) · Cardiovascular Agents (1) · Citrulline (1) · Docosahexaenoic Acids (1) · Famotidine (1) · Glutamine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hydroxyurea (1) · Hyperbaric Oxygenation (1) · Iloprost (1)
Pfizer (3) · Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · Mast Therapeutics, Inc. (2) · Novartis Pharmaceuticals (2) · Abigail Nixon (1) · Asklepion Pharmaceuticals, LLC (1) · Baylor College of Medicine (1) · Beni-Suef University (1) · Biossil Inc. (1) · Boston Children's Hospital (1) · Emmaus Medical, Inc. (1) · Forma Therapeutics, Inc. (1) · GlycoMimetics Incorporated (1) · Nantes University Hospital (1)
United States (17) · France (9) · Brazil (7) · Lebanon (7) · Turkey (Türkiye) (7) · Kenya (6) · Oman (6) · Colombia (5) · Saudi Arabia (5) · Canada (4) · Egypt (4) · Italy (4) · Nigeria (4) · Spain (4) · United Kingdom (4)
Anders Berggren, MD, PhD (2) · Ahmed F Mahmoud Hussein, MS.c (1) · Edwin L Parsley, D. O. (1) · Edwin L. Parsley, D.O. (1) · Matthew Heeney, MD (1) · Muzna Al Sawafi, MD (1) · Natasha Archer (1) · Nirmish Shah, MD (1)
PMID 35981565, PMID 37254256, PMID 30021096, PMID 31446143, PMID 33877274, PMID 35019238, PMID 35120836, PMID 35849650, PMID 37722599, PMID 38775255, PMID 40088922
2019 (3), 2017 (1), 2025 (1)